Alzheimer's Amyloid Drugs Fail: Landmark Review Finds No Cognitive Benefit Despite Brain Clearance

A major scientific review has delivered a devastating blow to the dominant theory of Alzheimer's disease treatment, concluding that drugs designed to clear amyloid plaques from the brain do not improve cognitive function or slow its decline. This finding directly challenges the foundational 'amyloid hypothesis' that has guided billions in pharmaceutical research and development for decades. The analysis indicates that successfully removing the protein, long considered the primary toxic culprit, does not translate to meaningful patient outcomes.

The review, synthesizing evidence from clinical trials, underscores a critical disconnect in Alzheimer's therapeutics. While these anti-amyloid biologics, such as lecanemab and aducanumab, demonstrably achieve their biochemical target—reducing amyloid burden in the brain—this action fails to halt or reverse the progression of memory loss and cognitive impairment. The failure suggests the disease's pathology is more complex than a simple cause-and-effect relationship with amyloid alone, potentially involving other factors like tau tangles or neuroinflammation that are not addressed by these therapies.

This revelation places immense pressure on drugmakers, regulators, and the research establishment. It calls into question the clinical and economic value of approved and pipeline medications costing tens of thousands of dollars annually. The findings will likely intensify scrutiny of regulatory decisions based on amyloid clearance as a surrogate endpoint and force a urgent re-evaluation of research priorities toward alternative mechanisms. For patients and families, it represents another profound disappointment in the long search for an effective treatment, highlighting the stubborn complexity of neurodegenerative disease.